Matt, Author at European Medical Journal - Page 199 of 212

Transforming Growth Factor Beta-Based Therapies, a Potential Modulator of the Immune Response in Type 1 Diabetes?

Immunobiological interventions are proving to be an exciting new area for mobilising the immune response towards certain tumours.

Treatment of Hypertension in New Frontiers

This symposium provided an excellent forum to discuss the global burden of hypertension, its challenges and approaches to best management.

New Paradigms in Heart Failure: RAAS Inhibition and the Management of Hyperkalaemia

This educational symposium discussed advances in blocking the renin–angiotensin–aldosterone system (RAAS) for patients with chronic systolic heart failure..

International, Large-Scale, Real-World Clinical Data Confirm the Safety Profile of Rivaroxaban

Rivaroxaban is a direct factor Xa inhibitor and a non-vitamin K antagonist (VKA) novel oral anticoagulant (NOAC) approved for a number of indications.

Real-World Registry Study Confirms Fondaparinux Over Low-Molecular-Weight Heparin for NSTEMI

The pivotal Fifth Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS-5) trial demonstrated that fondaparinux was non-inferior to…

Self-Expanding Coronary Stents: Rationale, Clinical Status, Future Prospects

The mechanical treatment of coronary artery stenoses by placement of balloon-expandable (Bx) coronary stents has become the most widely used invasive…

EMJ

Dr Jim Duthie, Our #EMJExpert, Answers Your Questions for Blue September

In support of Blue September, an annual campaign designed to raise global awareness for male related cancers, we invited world-renowned urologist Dr Jim…

EMJ

A Blue-ming Good Way of Promoting Men’s Health

Proudly supported by The Urology Foundation, Blue September is a fun way of delivering a serious message about ‘facing up to cancer in men’.

Non-Oral Drug Delivery Strategies: From Early Diagnosis to Advanced Treatments

This educational symposium, sponsored by Britannia Pharmaceuticals Limited, was held during the 1st Congress of the European Academy of Neurology (EAN)…

Hypothalamic–Pituitary Alterations in Patients With Neurosarcoidosis

Sarcoidosis is a non-caseating, granulomatous inflammatory disorder that can affect the central nervous system (CNS), including the hypothalamic–pituitary..